arrow
A

Anna Pellat

universite paris cite
H指数:20
被引数:1,246

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-Line Fluoropyrimidine- versus Gemcitabine-Based Chemotherapy for Metastatic Recurrence After Resection of Ampullary Adenocarcinoma: a Real-World Analysis of the FFCD-AC Cohort

壶腹腺癌切除术后转移性复发的氟嘧啶类与吉西他滨为基础的化疗比较:FFCD-AC队列的真实世界分析

2026-10-090
OAAI
Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61—FUNGEMAX trial (France)

纳曲伊立替康/5-氟尿嘧啶与吉西他滨/阿帕他汀相比纳曲伊立替康/5-氟尿嘧啶与吉西他滨/阿帕他汀在一线转移性胰腺癌中的序贯交替方案:法国随机II期PRODIGE 61—FUNGEMAX试验结果

2026-05-290
OAAI
Impact of germline MMR gene variants on immune checkpoint inhibitors response in patients with MSI-H/dMMR digestive cancers: a retrospective cohort analysis

胚系MMR基因变异对MSI-H/dMMR消化道癌患者免疫检查点抑制剂反应的影响:一项回顾性队列分析

2026-04-180
PRE
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: a retrospective study by AGEO

靶向疗法治疗转移性小肠腺癌的疗效:AGEO进行的一项回顾性研究

2026-03-280
PRE
Ability of computed tomography and endoscopic ultrasound to predict pTNM of resected ampullary adenocarcinomas (AC): an analysis of the French Fédération Française de Cancérologie Digestive AC prospective cohort study

计算机断层扫描和内镜超声预测切除的壶腹腺癌(AC)pTNM分期的能力:法国消化肿瘤学联合会(Fédération Française de Cancérologie Digestive)AC前瞻性队列研究的分析

2026-02-170
OAAI
ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI)

ESMO对基于AI的肿瘤学生物标志物的基本要求 (EBAI)

2025-11-180
OAAI
Occurrence of dMMR/MSI-H tumor during follow-up in Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic digestive cancer between 2015 and 2024: a retrospective analysis of a monocentric prospective cohort study

2015年至2024年间接受免疫检查点抑制剂治疗的转移性消化道癌症Lynch综合征患者随访期间dMMR/MSI-H肿瘤的发生:一项单中心前瞻性队列研究的回顾性分析

2025-09-090
OAAI
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study
2024-11-010
OAAI